Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Tranexamic Acid Improves Outcomes in TBI

Tranexamic Acid Improves Outcomes in TBI News & Analysis Clinical Trials Update Tranexamic Acid Improves Outcomes a lower risk of cardiovascular disease (CVD), in TBI reported a 20-year follow-up study in the Tranexamic acid reduces the risk of death New England Journal of Medicine. from mild to moderate traumatic brain in- Thefollow-upstudyexaminedcardiovas- jury(TBI)whentreatmentisdeliveredwithin cularoutcomesfrom184of214patientswith 3 hours, according to a trial in the Lancet. familial hypercholesterolemia who partici- The study randomized 12 737 patients pated in the original placebo-controlled trial with TBI to receive tranexamic acid (loading evaluating 2-year pravastatin efficacy and dose 1 g over 10 minutes then infusion of 1 g safety. Participants began taking the statin over 8 hours) or placebo. About 72% of pa- when they were between 8 and 18 years old; tients were treated within 3 hours of injury. themeanageatfollow-upwas31.7years.The The risk of injury-related death within 28 investigatorscomparedcardiovascularevents days was 18.5% in the tranexamic acid group betweenthenowadultparticipantsandtheir compared with 19.8% in the placebo group affected parents, for whom statins weren’t amongpatientstreatedwithin3hours.How- available until later in life. ever, tranexamic acid reduced death in pa- The cumulative incidence of cardiovas- Tranexamic acid can reduce death from TBI, tientswithmildtomoderateTBIbutnotinpa- cular events at age 39 years was 1% among according to a recent Lancet http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Tranexamic Acid Improves Outcomes in TBI

JAMA , Volume 322 (24) – Dec 24, 2019

Tranexamic Acid Improves Outcomes in TBI

Abstract

News & Analysis Clinical Trials Update Tranexamic Acid Improves Outcomes a lower risk of cardiovascular disease (CVD), in TBI reported a 20-year follow-up study in the Tranexamic acid reduces the risk of death New England Journal of Medicine. from mild to moderate traumatic brain in- Thefollow-upstudyexaminedcardiovas- jury(TBI)whentreatmentisdeliveredwithin cularoutcomesfrom184of214patientswith 3 hours, according to a trial in the Lancet. familial hypercholesterolemia who partici- The...
Loading next page...
 
/lp/american-medical-association/tranexamic-acid-improves-outcomes-in-tbi-cCqafwzf1S
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.20077
Publisher site
See Article on Publisher Site

Abstract

News & Analysis Clinical Trials Update Tranexamic Acid Improves Outcomes a lower risk of cardiovascular disease (CVD), in TBI reported a 20-year follow-up study in the Tranexamic acid reduces the risk of death New England Journal of Medicine. from mild to moderate traumatic brain in- Thefollow-upstudyexaminedcardiovas- jury(TBI)whentreatmentisdeliveredwithin cularoutcomesfrom184of214patientswith 3 hours, according to a trial in the Lancet. familial hypercholesterolemia who partici- The study randomized 12 737 patients pated in the original placebo-controlled trial with TBI to receive tranexamic acid (loading evaluating 2-year pravastatin efficacy and dose 1 g over 10 minutes then infusion of 1 g safety. Participants began taking the statin over 8 hours) or placebo. About 72% of pa- when they were between 8 and 18 years old; tients were treated within 3 hours of injury. themeanageatfollow-upwas31.7years.The The risk of injury-related death within 28 investigatorscomparedcardiovascularevents days was 18.5% in the tranexamic acid group betweenthenowadultparticipantsandtheir compared with 19.8% in the placebo group affected parents, for whom statins weren’t amongpatientstreatedwithin3hours.How- available until later in life. ever, tranexamic acid reduced death in pa- The cumulative incidence of cardiovas- Tranexamic acid can reduce death from TBI, tientswithmildtomoderateTBIbutnotinpa- cular events at age 39 years was 1% among according to a recent Lancet

Journal

JAMAAmerican Medical Association

Published: Dec 24, 2019

There are no references for this article.